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ABSTRACT
CffDNA screening is a powerful diagnostic tool in the prenatal diagnosis algorithm for chromosomal abnormalities. With 
detailed ultrasound examination as the mainstay of first-trimester risk assessment, cffDNA has been shown to be superior 
to first-trimester combined screening (FTCS) in false-positive rates for trisomy 21 detection. In light of the growing interest 
in cffDNA testing and the possibility of it replacing first-trimester biochemistry, we decided to investigate the usefulness of 
cffDNA tests in early-pregnancy risk assessment for preeclampsia (PE). The aim of this review paper was to evaluate clinical 
application of first-trimester cfDNA in predicting PE, as well as to investigate its possible use in first-trimester PE screening 
enhancement, also in cases where biochemistry is not performed.
Key words: cell-free fetal DNA; cffDNA; cell-free DNA; cfDNA; preeclampsia; PE; first-trimester screening; first-trimester 
combined screening
Ginekologia Polska 2019; 90, 1: 55–60
INTRODUCTION
In the 1990s, Lo et al., published a revolutionary paper 
describing the presence of cell-free DNA (cfDNA) of fetal 
origin (cell-free fetal DNA; cffDNA) in maternal circulation, 
and reported its increased concentrations in pregnancies 
affected by trisomy 21 [1, 2]. Since its clinical implementa-
tion in 2011, cffDNA testing has been confirmed as a highly 
accurate non-invasive screening test for trisomy 21 among 
various groups of patients [3]. Currently, cfDNA screen-
ing is a powerful diagnostic tool in the prenatal diagnosis 
algorithm for chromosomal abnormalities. With detailed 
ultrasound examination as the mainstay of first-trimester 
risk assessment, cffDNA has been shown to be superior to 
first-trimester combined screening (FTCS) in false-positive 
rates for trisomy 21 detection [4]. In light of the growing 
interest in cffDNA testing and the possibility of it replacing 
first-trimester biochemistry, we decided to investigate the 
usefulness of cffDNA tests in early-pregnancy risk assess-
ment for preeclampsia (PE). 
Following the Fetal Medicine Foundation principles, 
cffDNA test serves as a screening tool in the intermediate risk 
group only since high-risk groups require invasive testing 
and low-risk patients are managed expectantly. Some au-
thors have suggested an increased release of fetal DNA into 
the maternal bloodstream due to trophoblastic apoptosis in 
abnormal placentation disorders, such as PE or fetal growth 
restriction (FGR) [5]. PE complicates 2–3% of all pregnancies 
and, together with its most malignant form - eclampsia, is re-
sponsible for a great number of maternal deaths globally [6], 
posing a formidable challenge for maternal-fetal medicine. 
The aim of this paper was to review a potential role of 
cfDNA in maternal-fetal medicine with special regard for 
application of first-trimester cfDNA in predicting PE. The 
well-known and extensively described function in screening 
for trisomies was not included. It is believed that this article 
will provide insight into broader spectrum of cfDNA employ-
ment in diagnosis of pregnancy complication. 
Cell free fetal DNA and PE
Recent meta-analyses and the results of randomized 
controlled ASPRE trials triggered a serious interest in first-tri-
mester PE screening. A possibility of effective reduction in PE 
prevalence by early (before 16 weeks of gestation) implemen-
tation of aspirin has been recently well-described in the lit-
erature [7–9]. Although various studies report increased con-
centrations of cfDNA in women with confirmed PE, or shortly 
before the onset of PE, there is paucity of data on the pre-
dictive value of cfDNA testing at first-trimester visit [10, 11]. 
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Increased quantities of fetal and total cfDNA in women 
diagnosed with PE are probably the result of enhanced 
apoptosis of the trophoblastic cells resulting from placental 
ischemia, inflammatory processes, and reduced clearance 
of cfDNA from the maternal circulation [12]. Paradoxically, 
lower fetal fraction might originate from disturbed ratio of 
released cfDNA, with a more pronounced increase in the 
maternal fraction.  
Technology behind cffDNA
The initial detection of cffDNA was based on Y chro-
mosome-specific markers, narrowing the investigation to 
male-fetus pregnancies only. The discovery of an epige-
netic disbalance in maternal and fetal genes has brought 
a new approach to quantification, based on polymerase 
chain reaction (PCR). The promoter of the RASSF1A gene, 
hypermethylated in the placenta and hypomethylated in 
maternal blood cells, seems to be the appropriate candidate 
for digestion with methyl-sensitive restriction enzymes, 
which allows to detect placental-derived sequences in 
the maternal circulation [13, 14]. Despite the fact that this 
method might determine future directions for PE screening, 
risk should still be evaluated by means of non-PCR based 
first-trimester screening. Different methods widely used for 
commercial purposes include massively parallel shotgun 
sequencing (MPSS) and more selective methods, such as 
chromosome selective sequence analysis (CSS) or a single 
nucleotide polymorphism (SNP)-based analysis [15]. MPSS 
appears to be the most appropriate in surveying the content 
of maternal plasma DNA. MPSS works by analyzing millions 
or even billions of nucleic acids and comparing them with 
the reference sequence, which generates high costs. DNA 
molecules, acting as short fragments in human plasma, 
could be detected by commercial MPSS platforms, more 
efficient for analyzing highly fragmented DNA as compared 
to locus-specific methods of analysis [16]. With CSS or SNP 
methods, much less analysis is required since the assays 
are directed against specific regions, which significantly 
reduces the costs. Both methods are widely accepted as 
high-performance providers in cffDNA analysis, yet, to the 
best of our knowledge, there are no studies comparing the 
results in the same populations. An overview of the com-
mercially available methods for cfDNA testing is presented 
in Table 1. 
Commercial laboratories should present their methodol-
ogy and clinical validation data in detail. Moreover, quality 
metrics must be given for reliable reporting. Fetal fraction 
measurement could be used for laboratory comparison 
– low failure rate might indicate inaccurate assessment of 
low fetal fraction, and high failure rate may be expected in 
overly complicated tests or those of low performance [15]. 
Fetal fraction and maternal factors 
Associations between fetal fraction in maternal plasma 
and maternal characteristics were described extensively and 
most results are mutually comparable. Ashoor et al. [17] es-
timated median fetal fraction at 11–13 weeks of gestation to 
be 10%. In their study, fetal fraction decreased with maternal 
weight, increased with fetal crown-rump length, maternal 
serum level of free beta-hCG (free beta-human chorionic 
gonadotropin) and PAPP-A (pregnancy-associated plasma 
protein-A). Moreover, it was higher in smokers and in the 
presence of fetal trisomy 21. Ethnicity also plays a role in 
cffDNA fraction – women of Afro-Caribbean origin seem to 
have lower levels than Caucasians, yet the greatest depletion 
is provided by maternal weight - the estimated proportion 
of pregnancies with fetal fraction below 4% increased with 
maternal weight from < 1% at 60 kg to > 50% at 160 kg [17]. 
Similar results were reported by Revello et al. [18]. 
Fetal fraction decreased with growing BMI and maternal 
age and was also lower in women of South Asian origin 
than in Caucasians. It was higher in natural conception as 
compared to assisted reproduction techniques, and with 
higher levels of PAPP-A and beta-hCG. Median fetal fraction 
in the group unaffected by chromosomal trisomies was 
at the level of 11% (interquartile range, IR, 8.3%–14.4%), 
10.7 % in trisomy 21, 8.6% in trisomy 18, and 7.0% in trisomy 13. 
Fetal fraction concentration in relation to PE was also 
Table 1. An overview of the available methods for commercial cfDNA testing in maternal blood [34]
Method MPSS CSS SNP
Technique quantification of DNA fragments originating from any given chromosome
selective assays directed against specific 
regions on chromosomes 21, 18, 13, X, Y
analysis of differences in maternal and 
fetal single nucleotides within a given 
sequence
Advantages
+ fragments from all chromosomes are 
examined
+ low failure rate (< 2%)
+ possible microdeletion/
microduplication detection
+ reduced cost compared to MPSS
+ triploidy detection 
+ possible extension to selected 
microdeletion/
microduplication offered by a company 
Disadvantages - high cost - failure rate of 2–4% - failure rate of 3–5%
MPSS — massively parallel shotgun sequencing analysis; CSS — chromosome selective sequence analysis; SNP — selective nucleotide polymorphism analysis
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presented by Rolnik et al. [19]. First-trimester markers for 
preeclampsia (mean arterial pressure — MAP, uterine artery 
pulsatility index — UtAPI, PAPP-A and placental growth 
factor — PIGF) concentrations were analyzed alongside 
the baseline characteristics of the population. Gestational 
age as well as multiparity without history of PE or FGR had 
a positive association with fetal fraction. On the other hand, 
IVF conception, advanced maternal age, increased BMI, 
chronic hypertension, types 1 or 2 diabetes mellitus, and 
South Asian ethnicity were associated with diminished fetal 
fraction. Finally, MAP and UtAPI showed a substantial nega-
tive association with fetal fraction (r = -0.118, p < 0.001 and 
r = -0.064, p < 0.001 for MAP and UtAPI, respectively), and 
PAPP-A and PlGF had a significant positive association with 
fetal fraction (r = 0.219, p < 0.001 and r = 0.091, p < 0.001 for 
PAPP-A and PlGF, respectively). 
According to the literature, gestational age and inversely 
correlated maternal weight are the only two factors strongly 
influencing fetal fraction [20]. Other variables, e.g. ethnic-
ity, cigarette smoking or chromosomal aneuploidies, show 
confusing results and need further research [17].
Low fetal fraction and the risk for preeclampsia
The percentage of placental fraction in maternal circula-
tion is crucial to obtain informative and reliable results. Poor 
accuracy is related to low fetal fraction of cffDNA [21]. Most 
companies avoid presenting their results if placental frac-
tion is lower than 4%. Approximately 2–3% of the results 
are inconclusive due to logistic failures (specimen collec-
tion, storage or processing), or genomic irregularities (fetal, 
maternal, placental mosaicism, malignancy, other chromo-
somal abnormalities), with insufficient fetal fraction as the 
most common reason [22]. 
Rolnik et al. [19], supported the theory that low fetal 
fraction might be an implication of diminished placental 
mass and, consequently, an early marker of placental dys-
function. A total number of 4313 singleton pregnancies 
which had undergone cfDNA testing at the first trimester 
visit were analyzed for PE or FGR risk. Their study was the first 
analysis of a correlation between first-trimester fetal fraction 
and biophysical markers for PE. Lower fetal fraction was 
associated with higher risk for PE < 34 weeks, < 37 weeks, 
FGR < 37 weeks and correlated with higher MAP and UtAPI. 
On the other hand, fetal fraction was positively associated 
with PAPP-A and PIGF and could be partially predicted by 
maternal characteristics. Assuming a risk cut-off 1:100 for 
PE < 37 week gestation, median fetal fraction for the high-risk 
group was 10.4% (IQR 7.8, 13.2), compared to 11.8% (IQR 9.2, 
14.8) in the low-risk group (p < 0.001), which is consistent 
with the findings of another study with known pregnancy 
outcome — 11.04% in patients who did not developed 
PE as compared to 10.06% in PE patients (p < 0.0001) [23]. 
In that study by Norton et al., the association of UtAPI and 
PIGF with fetal fraction did not remain independently sig-
nificant after addition of PAPP-A to the multivariate model, 
probably due to its strong own association with fetal frac-
tion. The question remains whether fetal fraction incorpo-
rated to multi-marker screening would improve the accuracy 
of the test. Although its contribution may not be significant 
due to strong associations of PE with other well-described 
markers, it may play a role in cases without the results of 
placental biochemistry. The main limitation of the study by 
Norton et al., is lack of information whether women with low 
fetal fraction actually developed PE, although this observa-
tion probably could not have been made due to changes in 
the natural course of PE caused by aspirin implementation.
In a large pooled meta-analysis, Contro et al. [11], did 
not find usefulness of first-trimester cffDNA quantification 
for predicting PE measured by means of RT-PCR (reverse 
transcription polymerase chain reaction), a technique not 
used in commercially available cffDNA tests. A great strength 
of their review was the analysis of PE prediction not only in 
high-risk women but also those who subsequently devel-
oped PE. Still, these authors did not mention aspirin intake 
among their study population as a confounding factor. 
Despite a considerable number of reviewed papers, only two 
of them investigated cffDNA measured in the first trimester 
for PE prediction at any time during pregnancy (Tab. 2). 
Based on data shown in Table 2, it seems that at present 
first-trimester cffDNA cannot be used as a predicting tool 
for PE, since DR is too low to be clinically significant. Moreo-
ver, when Sifakis et al. [24], took into account late PE (after 
34 weeks of gestation), the difference between cffDNA levels 
became insignificant (all PE vs. controls — 71.2 vs. 51.5; late 
PE vs. controls — 50.8 vs. 51.5), which gives unacceptably 
low DR. In the study by Kim et al the DR rate was higher, 
although their study group was small — only 4 cases of PE. 
Despite many limitations of their analysis, the data were 
collected in a rigorous manner and merged into pooled 
analysis with recalculation of data distribution. 
Papantoniou et al., [25] quantitated both, cfDNA and 
cffDNA by determining RASSF1A levels before and after 
enzyme digestion (3.0 — fold and 20.0 — fold elevation, 
respectively) in women who subsequently presented PE, 
and referenced their results to uncomplicated pregnan-
cies. In the PE group, RASSF1A levels were significantly high-
er as compared to gestational-age-matched uncomplicated 
pregnancies (median cfDNA: 9402 gEq/mL vs 2698 gEq/mL; 
p = 0.000; gEq = genome equivalents). After enzyme diges-
tion and RASSF1A gene selective amplification, a 20-fold 
increase was observed (median cffDNA: 934.5 gEq/mL vs 
62 gEq/mL; p = 0.000). Thereby, cffDNA fraction of cfDNA 
could be estimated (2.16% and 14.4% in unaffected and PE 
pregnancies, respectively). 
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On the other hand, Silver et al., also used RASSF1A selec-
tive amplification and found no association between cffDNA 
in the first trimester and PE, although these authors did not 
detect cffDNA in the majority of cases and its assessment 
was not a primary desired outcome of their study, thereby 
the preparation process was suboptimal [26]. 
Kim et al. [6], presented an interesting implementation of the 
RASSF1A gene. Quantification of DSCR3 and RASSF1A as mark-
ers of cffDNA and the HYP2 gene as cfDNA was performed and 
incorporated into a contingent model. CfDNA as a single marker 
appeared to be more useful than cffDNA quantification in PE 
prediction (Tab. 3), although low DR of all of these single markers 
implies validity of its application only after adding other factors. 
Poon et al. [27], analyzed a cffDNA quantification meth-
od implemented in commercially available screening tests, 
i.e. chromosome-selective sequencing of non-polymorphic 
and polymorphic loci, where fetal alleles differ from ma-
ternal alleles. As a result, assessment of fetal and maternal 
cfDNA levels was unlikely to predict subsequent PE (12.9 and 
13.3 for PE and normal pregnancies, respectively) and mater-
nal plasma levels of cffDNA at 11–13 weeks of gestation were 
increased, alongside markers of placental development, and 
decreased by maternal weight. 
In order to adjust values to maternal characteris-
tics and gestational age, a different mode of quantifi-
cation was presented by Rolnik et al. [28], where total 
cell-free and fetal fractions were converted to multiples 
of median (MoM). At 11–13 weeks of gestation, there 
was a significant increase in total cfDNA (2.104 GE/mL 
vs. 1.590 GE/mL) and decrease in median fetal fraction 
measured by SeqFF (6.8% vs. 8.7%), although the differ-
ences faded after MoM calculations (controls — 0.963 and 
1.037; early PE — 1.199 and 0.993; late PE 1.138 and 0.969, 
total and fetal fraction, respectively). 
Thurik at el. [29], also converted first-trimester cffDNA 
values to MoM, failing to present predictive values for PE. 
These authors sought to determine the association between 
the adjusted cffDNA levels with the so-called ‘great obstetri-
cal syndromes’ – preeclampsia, pregnancy-induced hyper-
tension, gestational diabetes mellitus and spontaneous 
preterm birth, with quantification only in the male fetuses as 
a main disadvantage of the study. The MoM values were low-
er in women who later developed PIH (pregnancy induced 
hypertension), but not PE. Alongside many other studies, 
also in their research cffDNA levels were negatively associ-
ated with BMI and smoking, yet positively with PAPP-A.
Table 3. Comparison of predictive values for PE of single markers and levels and MoM values of DSCR3, RASSF1A, and HYP2 in the first trimester. 
Data are expressed as median (interquartile range)
AUC (95% CI) P VALUE
DETECTION RATE CONTROLS n = 53 PE n = 14
5% FPR 10% FPR Copies/mL MoM Copies/mL MoM
DSCR3 0.563 (0.435–0.685) 0.4499 16.2 23.0 890.9 (538.9–1,530.0) 
1.000 
(0.605–1.717) 
939.1 
(685.5–1,718.2) 
1.054 
(0.769–1.929) 
RASSF1A 0.617 (0.489–0.734) 0.1358 15.0 30.1 445.6 (262.9–936.4) 
0.912 
(0.538 – 1.916) 
668.8 
(455.5–961.6)
1.369 
(0.932–1.968) 
HYP2 0.682 (0.557–0.790) 0.0268 32.8 45.2 5,188.1 (2,042.6–7,682.5) 
0.921 
(0.363–1.364) 
7,169.6 
(4,895.2–12,384.1)
1.273 
(0.869–2.198) 
Table 2. Actual cffDNA values, estimated DR and AUC at a 10% false positive rate cffDNA in first-trimester screening 
Author
Kim et al. [35] Sifakis et al. [24] 
Weeks 7–14 11–14
No. of controls 36 176
No. of cases 4 44
Marker RASSF1A DYS
Actual cffDNA values 60.2 ± 9.7 — controls119.6 ± 52.2 — cases
51.5 (31.1–84.9) — controls
71.2 (30.3–107.4) — cases
Estimated DR (95 % CI) 75% (30.0–95.4) 20.5% (11.1–34.5) 
Estimated AUC (95% CI) 0.750 (0.412–1.00) 0.636 (0.539–0.773)
P-value 0.105 0.005 
Power at 5% type I error [%] 38.5 81.6 
cffDNA — cell free fetal DNA; SD — standard deviation; DR — detection rate; CI — confidence interval; AUC — area under the curve 
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SUMMARY
Over the last decades, second-trimester aneuploidy screen-
ing has been displaced by the first-trimester complex approach. 
It is highly probable that non-invasive prenatal testing (NIPT) 
with the use of cffDNA will be incorporated into the routine 
11–13-week scan. The emerging need for prevention rather 
than treatment of perinatal complications implies broadening 
of first-trimester screening. Detailed analysis brought new, 
mostly incidental applications of NIPT. Circulating tumor DNA 
(ctDNA) has the ability to distort the reading of the test. Altered 
genetic profiles were associated with increased incidence of 
maternal malignancy [30], including ovarian cancer (OC), which 
could improve the OC screening process [31]. 
Moreover, Bennett et al., proposed to use NIPT for de-
tecting BRCA1/2 mutations [32], starting a holistic model of 
insight into the maternal and fetal genome.
In most of the presented studies, no association be-
tween first-trimester cffDNA and subsequent development 
of preeclampsia was confirmed. Heterogeneity of the en-
rolled groups and multiple types of assessment methods 
make it difficult to draw clear conclusions. Moreover, most 
of the studies were based on older quantifying methods, 
dependent on fetal sex, and large-scale research should 
be planned, including implementation of massively parallel 
sequencing and digital analysis of selected regions [16, 33]. 
It is more likely that those instruments would answer the 
question whether deviation in first-trimester cffDNA concen-
tration could predict preeclampsia. Also, the majority of the 
researchers implemented markers not used in commercially 
available tests, which implies additional assays and does not 
fulfill the principles of screening per se. 
The presented data could lead to the hypothesis that 
first-trimester cffDNA levels are strongly dependent on the 
extent of placentation and maternal characteristics (such 
as volume of distribution related to BMI). Conversely, in late 
pregnancy, elevated cffDNA levels might be the result of im-
paired cell turnover and progressive placental insufficiency, 
leading to hypoxia and subsequent augmented apoptosis. 
A contingent model integrating maternal characteris-
tics and cffDNA values is yet another approach, which may 
be used for PE screening, as low fetal fraction is related to 
many PE risk factors, such as high median maternal BMI [28]. 
The abovementioned conclusions indicate a great need 
of large-scale surveys, which will take into consideration 
distribution, methods of analysis, maternal characteristics, 
sample consistency, and subsequent perinatal results. This 
approach could identify the ‘low fetal fraction’ group and its 
impact on pregnancy management. Hopefully, the future 
will bring the answer to the question whether low or very 
high fetal fraction values, or even failed results, are indica-
tions for intensified supervision, such as aspirin implementa-
tion or active chromosomal abnormality search. 
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